Amel Chaabane

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2252166/publications.pdf

Version: 2024-02-01

40 papers

476 citations

758635 12 h-index 19 g-index

47 all docs

47 docs citations

47 times ranked 550 citing authors

#	Article	IF	Citations
1	Risk factors of isoniazid-induced hepatotoxicity in Tunisian tuberculosis patients. Pharmacogenomics Journal, 2017, 17, 372-377.	0.9	32
2	Influence of combined <i>CYP3A4</i> and <i>CYP3A5</i> single-nucleotide polymorphisms on tacrolimus exposure in kidney transplant recipients: a study according to the post-transplant phase. Pharmacogenomics, 2015, 16, 2045-2054.	0.6	30
3	Hypersensitivity to amoxicillin after drug rash with eosinophilia and systemic symptoms (DRESS) to carbamazepine and allopurinol: a possible coâ€sensitization. British Journal of Clinical Pharmacology, 2010, 70, 273-276.	1.1	29
4	Carbamazepineâ€induced DRESS and HHV6 primary infection: The importance of skin tests. Epilepsia, 2008, 49, 1630-1633.	2.6	28
5	Clinical features, culprit drugs, and allergology workup in 41 cases of fixed drug eruption. Contact Dermatitis, 2019, 81, 336-340.	0.8	28
6	Hypersensitivity Syndrome Induced by Anticonvulsants: Possible Crossâ€Reactivity Between Carbamazepine and Lamotrigine. Journal of Clinical Pharmacology, 2009, 49, 1488-1491.	1.0	27
7	Acute generalized exanthematous pustulosis (AGEP) induced by cefotaxime. Fundamental and Clinical Pharmacology, 2010, 24, 429-432.	1.0	27
8	Severe ranitidine-induced anaphylaxis: a case report and literature review. Journal of Clinical Pharmacy and Therapeutics, 2012, 37, 494-496.	0.7	21
9	Albendazole-induced associated acute hepatitis and bicytopenia. Scandinavian Journal of Infectious Diseases, 2014, 46, 149-151.	1.5	18
10	Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) Probably Induced by Cefotaxime: a Report of Two Cases. Clinical Medicine and Research, 2012, 10, 32-35.	0.4	13
11	Limited Sampling Strategy of Mycophenolic Acid in Adult Kidney Transplant Recipients: Influence of the Postâ€Transplant Period and the Pharmacokinetic Profile. Journal of Clinical Pharmacology, 2013, 53, 925-933.	1.0	13
12	Lichenoid Eruption Associated with Hydrochlorothiazide and Possible Cross Reactivity to Furosemide. Therapie, 2009, 64, 344-347.	0.6	11
13	Fixed Drug Eruption: Levofloxacin, Another Culprit Drug. Journal of Clinical Pharmacology, 2012, 52, 775-777.	1.0	9
14	Piroxicamâ€induced fixed drug eruption: Crossâ€reactivity with meloxicam. Contact Dermatitis, 2019, 81, 24-26.	0.8	9
15	Human Intravenous Immunoglobulin—Induced Aseptic Meningitis: A Case Report. Journal of Clinical Pharmacology, 2012, 52, 279-281.	1.0	8
16	Tacrolimus therapeutic drug monitoring in Tunisian renal transplant recipients: Effect of post-transplantation period. Transplant Immunology, 2013, 28, 198-202.	0.6	8
17	Captopril-Induced DRESS. Dermatitis, 2013, 24, 255-257.	0.8	7
18	Effect of CYP3A4*22 and CYP3A4*1B but not CYP3A5*3 polymorphisms on tacrolimus pharmacokinetic model in Tunisian kidney transplant. Toxicology and Applied Pharmacology, 2020, 396, 115000.	1.3	7

#	Article	IF	Citations
19	Fixed Drug Eruption: a Selective Reaction to Amoxicillin. Therapie, 2013, 68, 183-185.	0.6	6
20	The rest of the story of the patient described in the letter to the editors: â€Hypersensitivity to amoxicillin after… (DRESS) to carbamazepine…: a possible coâ€sensitization'. British Journal of Clinical Pharmacology, 2016, 81, 784-785.	1.1	6
21	Circadian variation of isoniazid pharmacokinetics in mice. Biomedicine and Pharmacotherapy, 2016, 84, 1150-1155.	2.5	6
22	Therapeutic drug monitoring of caffeine in preterm infants: Could saliva be an alternative to serum?. Therapie, 2017, 72, 685-689.	0.6	6
23	Codeine-induced acute generalized exanthematous pustulosis without <i>IL36RN</i> mutations. Pharmacogenomics, 2018, 19, 889-893.	0.6	6
24	Influence of CYP3A polymorphisms on tacrolimus pharmacokinetics in kidney transplant recipients. Pharmacogenomics Journal, 2021, 21, 69-77.	0.9	6
25	Clinical and genetic influencing factors on clozapine pharmacokinetics in Tunisian schizophrenic patients. Pharmacogenomics Journal, 2021, 21, 551-558.	0.9	6
26	Colloidal silica-induced hypersensitivity: myth or reality. International Journal of Clinical Pharmacy, 2016, 38, 7-9.	1.0	5
27	Limited sampling strategy for predicting isoniazid exposure in patients with extrapulmonary tuberculosis. Journal of Clinical Pharmacy and Therapeutics, 2020, 45, 503-512.	0.7	5
28	Erythema nodosum induced by Covidâ€19 Pfizerâ€BioNTech mRNA vaccine: A case report and brief literature review. British Journal of Clinical Pharmacology, 2023, 89, 536-540.	1.1	5
29	Development of Limited Sampling Strategies for the Estimation of Tacrolimus Area Under the Curve in Adult Kidney Transplant Recipients According to the Posttransplantation Time. Therapeutic Drug Monitoring, 2015, 37, 524-530.	1.0	4
30	Celecoxibâ€induced bullous fixed drug eruption: An unusual presentation. British Journal of Clinical Pharmacology, 2019, 85, 2638-2639.	1.1	4
31	Development of a population pharmacokinetic model and Bayesian estimators for isoniazid in Tunisian tuberculosis patients. Pharmacogenomics Journal, 2021, 21, 467-475.	0.9	3
32	Association of non-immediate drug hypersensitivity with drug exposure: A case control analysis of spontaneous reports from a Tunisian pharmacovigilance database. European Journal of Internal Medicine, 2018, 53, 40-44.	1.0	2
33	Drug Rash with Eosinophilia and Systemic Symptoms: Captropril, an Unusual Culprit Drug. Dermatitis, 2019, 30, 238-239.	0.8	2
34	Cefotaximeâ€induced drug reaction with eosinophilia and systemic symptom in a child with crossâ€reactivity to other cephalosporins and cosensitization to teicoplanin. British Journal of Clinical Pharmacology, 2023, 89, 544-550.	1.1	2
35	Delayed Crossâ€Reactivity Between Cyclophosphamide and Chlorambucil. Journal of Clinical Pharmacology, 2012, 52, 771-774.	1.0	1
36	Celecoxib induced bullous eruption confirmed by a patch test. Clinical and Translational Allergy, 2014, 4, P81.	1.4	1

#	Article	IF	CITATIONS
37	Beta″actam hypersensitivity in children: Frequency and risk factors. British Journal of Clinical Pharmacology, 2023, 89, 150-157.	1.1	1
38	Acute generalised exanthematous pustulosis (AGEP) after cefotaxime use. BMJ Case Reports, 2009, 2009, bcr0620080343-bcr0620080343.	0.2	1
39	Circadian variation in intestine toxicity of Mycophenolate mofetil in rats: an experimental and histopathologic study. Biological Rhythm Research, 2020, 51, 408-420.	0.4	O
40	Isoniazid Therapeutic Drug Monitoring in Tunisian Patients With Tuberculosis. Journal of Clinical Pharmacology, 2021, 61, 972-978.	1.0	O